Herbal medicine at a crossroads. by Taylor, D
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ofthese products from a conventional med-
ical perspective, not on the effects of and
reasons for this rising demand on quality
standards and supply.
The World Health Organization esti-
mates that up to 80% ofthe world's popula-
tion relies on traditional medicinal sys-
tems-not Western medicine-and in many
ofthese systems herbal medicine plays a key
role. In the United States, according to a
survey published in the NewEnglandJournal
ofMedicine in 1993, nearly one in three
Americans surveyed use some kind of alter-
native medical treatment.
In the past year and a half, U.S. debate
over herbal medicines has arisen again,
fueled by legislation that moves closer to
acknowledging the role of herbal medicines
as a complement to Western medicine. On
the one hand, a 6 May 1996 Newsweek
cover story announced the dangers of an
unregulated herbal drug industry. The arti-
cle followed an FDA warning against all
products containing ephedra-a stimulant
derived from Ephedra sinica used to control
weight and boost energy- and the report of
I On'the othe
essor of family me
ng University and chair ofth
sory council to the NIH Office o
ernative Medicine has published a new
ook, Manifestofora New Medicine, that he
describes as a primer for physicians as well as
the public on how to use complementary
forms of medicine, including herbal medi-
cines, as tools in a new partnership for
health. "In one sense, that kind ofattention
is fine," says Gordon of the Newsweek arti-
cle. "We all need to become more attentive
to what we do." The article, he notes, con-
firms the growing importance of herbal
products and the fact thatAmericans arejust
now approaching a better understanding of
them.
Regulation
As herbal medicine use has increased, coun-
tries have wrestled with the need to regulate
these products for public safety. In Japan,
where only physicians practicing Western
medicine are licensed, the growing populari-
tyofkampoUapanese herbal medicine in the
Chinese tradition) has challenged the med-
ical system. Kampo, the primary form of
medicine in Japan up to the mid-1800s, is
less targeted against disease than Western
medicine, and in fact, does not assign names
to diseases; nonetheless, scientific studies
have confirmed the effectiveness of some
kampo remedies. In the 21 August 1993
issue of The Lancet, Catrien Ross reported
that 70% ofJapan's more than 200,000
doctors (including all doctors aged 30-40
meclcine in west uermany, 7r
than 5 million prescriptions were written.
The German herbal product market has
grown from an estimated $1.7 billion in
1989 to $3 billion in 1995. To monitor
these products, the German government has
prepared monographs defining quality stan-
dards and potency tests for over 350 single-
plant drugs. Known as the Commission E
monographs, they include descriptions of
uses, contraindications, side effects, and
dosages.
France has also officially recognized
more than 200 medicinal plants and provid-
ed specifications governing their sale. To
advance the state of herbal medicine,
European trade associations formed the
European Scientific Cooperative for
Phytotherapy (ESCOP) under the auspices
of the European Economic Community
(EC). ESCOP is publishing a series ofplant
species monographs for EC marketing
authorization.
The British appear to be moving in the
same direction. The 22 April 1995 issue of
the British MedicalJournalincluded an arti-
cle suggesting that special licensing ofherbal
medicines for treatment of minor illnesses
may be the best way to safeguard public
health. Peter A. G. M. De Smet, a Dutch
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pharmacist, wrote that the aim ofsafeguard-
ing public health "is not well served when
the stringent application ofconventional cri-
teria to herbal medicine-like products leaves
most such products outside strict regulatory
control." The article suggested practitioners
should be licensed with the obligation to
report adverse reactions, and that mecha-
nisms for postmarketing surveillance be
instituted.
In the United States, regulation of
herbal medicine-type products changed in
1994 with the passage of the Dietary
Supplement Health and Education Act
(DSHEA). This law reclassified herbal prod-
ucts, along with vitamins and minerals, as
dietary supplements-a category somewhere
between food and over-the-counter drugs.
Under the DSHEAlaw, a manufacturer may
make structure-function daims for a prod-
uct on its label, provided these claims are
supported by scientific evidence. This places
the burden of proof on the FDA to show
that a product poses danger before it can
restrict sales.
In January 1996, following a schedule
set forth in the new law, the FDA proposed
new labeling rules for dietary supplements,
including herbal medicinal products. The
standards would follow the same basic for-
mat as for processed foods regarding nutri-
tional information, but would permit prod-
uct labels to list "nonessential dietary ingre-
dients, such as herbs." The rules are expect-
ed to be finalized and in effect by early
1997.
Federal Research
The consequences ofthe DSHEA for federal
research on herbal products
is not yet dear. The FDA's
role is still to supervise, but
not conduct, clinical trials
of new medicines, accord-
ing to Brad Stone, an FDA
spokesman. The FDA does
not determine the nature of
the clinical methods or
what products to study,
although it does review
research plans for scientific Mm
andethical standards.
In late 1995, the FDA
examined adverse reaction O,40
reports to determine UsHab
whether herbal products Pt0 pee
containing ephedra should liver
be restricted. InApril 1996, S4 Hel$
the FDA issued a warning
on ephedra-containing kX
dietary supplements sold as prtete a
a substitute for "street damaefro
drugs." The statement cau- nrt
tioned consumers not to
buy ephedra-containing
products that are packaged as
safe and natural substitutes
for illegal drugs such as
"ecstacy," because they can
have "potentially dangerous
effects on the nervous system
and heart."
The FDA warning sug-
gests that the need for the
agency's investigations to
proceed case by case have
slowed the regulatory
process. To get past the
product-bys-product backlog, Ori
the FDA has published con- US$12Trea
sumer information on some TI ofthe broader issues, such as D 350
how to choose alternative tosw
medical treatments. d
When Newsweek pub- and ex
lished its cover storyamonth antiv
after theApril FDAwarning,
it focused on the lack of
strict regulation and cases ofabuse, especially
that of a 20-year-old college student who
died shortly after taking eight pills of an
ephedra product. And although the article
ended with recognition that the risk from
these products is small relative to prescrip-
tion drugs, it suggested that the FDA had
dropped the ball in its failure to press quickly
formandatorywarninglabels.
A number of federal agencies conduct
research related to herbal medicines, with
differing mandates. These include the
National Toxicology Program (NTP), the
FDA's National Center for Toxicological
Research, and the National Cancer Institute
(NCI). NTP studies focus
y mainly on potential public
j health risks like genetic
toxicology (including
mutagenicity) and long-
term effects including can-
cer risks. These studies are
typically coordinated with
all regulatory agencies that
aim to protect worker,
consumer, and environ-
mental health. The EPA,
a u CkSl00 SS04 for example, uses NTP
studies in its regulation of
d wpe
$f S V C Xinsecticides andpesticides.
seed hr2,000 James Huff, a re-
ItSlid repair searcher with the NIEHS
ae S 0SESx0(wherethe NTP is locat-
egeneratelver ed), estimates that one-
y*lcoliol and third of the 450 chemicals ipatiu azid sss ka¢0 theNTP has tested for car-
cinogenicity are "natural"
-rays and the chemicals, but not neces-
hyltin sul&te. sarilyherbal medicines. For
exaple t NTP studie
-
ephedrine sulfate in
J 1986, and found no evi-
I dence of carcinogenicity
in experimental animals.
Riddelliine, a naturally
occurring pyrrolizidine
alkaloid in some herbal
teas (as well as a contami-
nant in honey, meat,
grains, and milk) was the
subject ofshort-term tox-
icity studies in 1993 and
was found to cause cancer
in rats afteronly 13 weeks
EaX RS adV:Aruro C0ofexposure.
his2$ andcold, The FDA's National
0mune *S)ist>ii: : Center for Toxicological ue of Research conducts studies
ategrowthand mainly on the biological
im n sysm mechanisms of action
i underlying the toxicity of
activity, products regulated by the
FDA, accorcdng to spokes-
man Victor Attwood. In
coordination with the NTP, the centerconducts
bioassays on specific compounds, but generally
hasnotstudiedherbalmedicines.
In the course ofmonitoring endangered
species, the Forensic Laboratory ofthe U.S.
Fish and Wildlife Service studied imported
herbal products for components derived
from endangered species, such as bear bile
and musk excretion. Evidence of the rare
species were seldom present, says the labora-
tory's deputy director, Ed Espinoza, but they
found that the products did contain arsenic
and mercury. In September 1995, Espinoza
and his colleagues reported their findings in
the NewEnglandJournalofMedicine, noting
that by taking the dosage recommended on
the label ofa Chinese herb ball product, an
adult could consume up to 73 mg ofarsenic,
and more than 1200 mg ofmercury daily-
more than four times the amount reported to
cause chronic mercury sulfide poisoning.
"Health care professionals should be aware
that patients who consume traditional
Chinese remedies may be exposed to many
potentially toxic substances," they wrote.
The same may be said of pharmaceutical
drugs, ofcourse; the main difference is that
for herbal remedies, methods for assessing
ingredients and labeling products have not
yet been standardized.
Most federal research that scientifically
evaluates potential medicines takes place at
the NCI. The institute's ongoing program
for screening natural products for anticancer
and anti-AIDS properties tests samples of
plants, herbs, microbes, and marine life
against 60 types of human cancer and the
AIDS virus. It's an early step in the process
that leads to dinical trials and FDA approval
as adrug.
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Within the National
Institutes of Health, princi-
pal responsibility for study-
ing herbal medicines lies
with the Office ofAlternative
Medicine (OAM), created in
1991. Through several series
of peer-reviewed grants, the
OAM set about evaluating
therapies as diverse as home-
opathy, acupuncture, and
music therapy. After the first
round of small grants in
1993-1994, the OAM has OrSiv: J
concentrated on using its UNSPt
grants to foster centers of to :reat SyJ
study. SUW
In December 1994, the let5.I1C0 ',
OAM published Alternative
Medicine: ExpandingMedical
Horizons, a comprehensive alertness, at
overview ofthe mainfields of Stim
alternative medicine and an reduced ca
outline of research needs. Inhibitsdete
The report's section on thi
herbal medicines cites scien-
tific studies from Europe and Asia that con-
firm health benefits ofparticular remedies.
The report also notes that "the current regu-
latory mandate puts the FDA in a difficult
position. It is expected to 'protect the public'
but has no expertise or resources to evaluate
the global herbal medicine inventory ...
Instead of expecting the FDA to be an
omnipotentprotector, Congressshouldlegis-
late a more educational, informational role,"
for example, by establishing certification of
herbal content and potency for indusion on
labels.
The American Medical Association's
(AMA) position on herbal medicines remains
one ofwary interest. The AMA encourages
physicians to report to the FDA any adverse
effects attributed to herbal medications. The
association is "very interested" in the OAM-
sponsored research, according to AMA press
officer James Stacey. However, according to
AMA Assistant Director for Media Brenda
Crane, the FDA's MedWatch program only
allows reports ofnegative effects. "There is no
program for reporting positive effects," she
says. "That'sjustthewaythesystemissetup."
Benefcial Effcs Confirmed
For centuries, plant-based folk remedies have
provided a basis for Western medicine's
pharmaceutical research. The discovery of
Digitalis's effectiveness as a treatment for
cardiac patients started with a folk healer in
Shropshire, England, in the 1780s. With the
advent ofsynthetic compounds in the 1950s,
however, ethnobotany-the study of the
relationships between plants and people-
declined as a source ofpharmaceutical leads.
In the last decade, eth-
nobotany has reemerged, - with a growing number
ofscientists being trained
and willing to do the
needed field work, and
more sophisticated tech-
nologyavailable for bioas-
says. Such bioassays can
now test plant com-
pounds quickly against a
wide range ofhuman dis-
eases. These technological
peandAsia advances have also fueled usedinEurPe investment in "biodiversi- om faging. o bgin ty prospecting," a wider :essbramin,' &i:St4X, . approach than ethnob- ygnd 'wn otany that involves per-
ity,rientation, forming broad invento-
tion, mental ries ofspecies in diverse
eceetmemory. ecosystems. The most
rcularion and publicized biodiversity
nras risks, prospecting agreement, t in in between Merck Pharma-
deny. ceuticals and Costa Rica,
has involved more than
$2 million since 1992 to study and conserve
tropical forests. Bristol-Myers Squibb, Pfizer,
and the NCI have also invested millions in
biodiversity prospecting in this decade, usu-
allyin tropical forests.
It is widely held that about one quarter
of Western medicines are derived from
plants, although a recent study led by
Francesca Grifo, director of the Center for
Biodiversity and Conservation at the
American Museum ofNatural History, puts
the figure closer to 60%. Most Western
plant-derived medicines,
however, resulted from iso-
lating active ingredients and
not from the complex com-
pounds that make up most
herbal remedies. Somescien-
tists apply the term "botani-
cal" to anyproduct that con-
tains ingredients ofvegetable
matter orits constituents as a
finished product.
Research continues to
accumulate evidence for and Gzn
against herbal medicines.
Scientific research on many On
herbalmedicines hasshown a UUd1
clear correlation with health
benefits. For Ginkgo biloba, Q tobeefc for example, the NIH's
Alternative Medicine report
cites more than nine pub-
lished scientific studies, con-
ducted mostly in Europe, 0: ac
confirming ginkgo's effec- .cut#
tiveness in improving cogni-
tive function and circulation, !Vg;0:
and in reducing the riskofcardiovascular dis-
ease. The report also cites findings confirm-
ing the benefits ofmilkthistle (Silybum mari-
anum, used both to prevent and repair liver
damage), saw palmetto (Serenoa repens, effec-
tive against benign prostatic hypertrophy),
and echinacea (Echinacea purpurea and
Echinacea angustifolia, found to have
immune-enhancing and antibacterial proper-
ties), amongothers.
Some remedies have been proven to
have targeted effects against serious health
risks. Sho-saiko-to (a Japanese kampo medi-
cine composed ofparts of Bupleurumfalca-
tum, Pincilia ternata, Scutellaria baicalensis,
Panax ginseng, Zizyphusjujuba, Blycyrrhiza
uralensis, and Zingiber officinale) was found
by researchers at Osaka City General
Hospital to correspond with lower rates of
liver cancer among cirrhosis patients. The
study by Hiroko Oka and colleagues, pub-
lished in the 1 September 1995 issue of
Cancer, looked at 260 cirrhosis patients over
5 years; halfwere given Sho-saiko-toand con-
ventional medicines, while the other half
received only the conventional treatment.
Only 23 (17.7%) of the Sho-saiko-to recipi-
ents developed liver cancer, compared to 33
(25.4%) of the patients receiving conven-
tional treatment.
Adverse Reactions
Apart from occasional cases of intentional
abuse, adverse physical reactions to botanical
products are usuallycausedbyadulteration or
contamination ofproducts during prepara-
tion or packaging, or mistaken plant identifi-
cation in cases of self-treatment. Recent
reports have shown poten-
tial negative effects of
chaparral (Larrea tridenta-
ta) and certain herbal teas,
in addition to the
ephedrine products and
imported herb balls men-
tionedabove.
A letter exchange in
the 20 September 1995
issue of theJournal ofthe rhl:~; ;i77 Amencan MedicalAssocia-
tionhighlights the need
for more precise descrip-
1China' tons as a first step toward
reat understanding botanical
ddtiabe#~. W00 remedies unfamiliar to
11581)050aliOWil Western medicine. Several
3 ; ~ letters criticized an article
on thepossible liver toxic-
7 0 ; ity of chaparral for its
vague use ofthe common
name "chaparral" and for
implying that it is an
herb, rather than awoody
:t;;x ¢::W>Xperennialshrub. Inreply,
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the artide's authors agreed that "more careful
attention to plant taxonomy is appropriate"
among physicians "because of the growing
use ofalternative remedies."
Research Hurdles
When medical systems collide, conventional
methods for studying efficacy may no longer
apply. Western medicine's search for active
ingredients is thwarted by the chemically
complex nature ofbotanical remedies-pro-
ponents say that the activity of a remedy's
ingredients is synergistic and balanced for a
therapeutic effect greater than that of any
individual ingredient. "The research on herbs
tells us that each has specific chemicals with
specific effects," observes Gordon in his
book. "It doesn't, however, begin to address
the question ofthe correspondences between
the Chinese theory of their action and the
Western chemical analysis."
Besides these technical issues, propo-
nents who would like to see herbal medi-
cines treated as drugs also point to the finan-
cial barriers. The years of clinical trials
required for FDA drug approval can cost
$100-500 million for a single drug-feasi-
ble for large pharmaceutical corporations
with patentable products, but not for small
manufacturers of herbal products without
clear patent protection.
A further institutional problem is the
apparent lackofa framework that documents
both health benefits and toxicity risks. The
FDA issues statements mainly to warn the
public against potential health risks. Health
careproviders and thepublic, however, desire
substantiated reports aboutpotential benefits,
manyofwhichhaveappeared
injournals in Europe but not
in America. There appears to
be no database in English
that catalogs risks of herbal
medicines together with doc-
umented remedies. To
address this need, the
American Botanical Council,
anonprofit research organiza-
tion based in Austin, Texas,
will publish a translation of
the German Commission E
monographs this fall.
Still, opposing sides O I
appear to be converging. The
nonprofit National Council Usi:Trc
Against Health Fraud
(NCAHF) put forward label-
ing recommendations in its ,
July-August 1995 newslet- ha ead
ter. Like the American d s ad
Botanical Council, the tion (L
NCAHF called for a special sul
category of over-the-counter inantitc
medicines. While the two
groups differ as to suggest-
ed label wording, both
propose that labels identify_
plant sources by their sci-
entific names and include
a toll-free telephone num-
ber for consumers to re-
port adverse reactions. The
NCAHF cautions con-
sumers to buy only those
products that identify plant
species and state contraindi- N..0 (A
cations, and to consult a
physician before using an iI
herbal therapy while taking U Used
othermedication. tu ro
Other countries' 0aiids isdrnk experiences in integrating S
Western and traditional
herbal medical systems pepk; ic
show a pattern ofdialogue in -S s
and gradual institutional raio It
change. In Sri Lanka, n
where the ancient Indian
practice ofAyurvedic med-
icine coexists with Western medicine, the
process started in 1929 when the British
colonial administration established a separate
College ofIndigenous Medicine. By the late
1950s, the Sri Lankan Health Ministryhad a
department devoted to promotingAyurveda,
and in the 1970s, the College ofAyurveda
became affiliated with the University of
Colombo. Ayurvedic practitioners in Sri
Lanka are required to have a license, and tra-
ditional Ayurvedic knowledge is being cata-
loguedwith government andUnitedNations
support. Public hospitals and over 300 cen-
tral dispensaries now pro-
videAyurvedic treatment,
_ according to Upali Pilipitiya,
director of the Bandar-
anaike MemorialAyurvedic
Research Institute, which
conducts clinical research
on Ayurvedic medicine's
effects against rheumatoid
arthritis, diabetes melli-
tus, bronchial asthma,
leukoderma, psoriasis,
and chronic headaches.
MoreSws ofChange
an :- 000000llf0tiFor years, practitioners of
gulcerS and complementary medicine
-phiJis, C 0ldS in the United States have
feer a ili$$00sought the opportunity to
t register with authorities,
on : t ifs herb's like their counterparts in
anthe lobela Sri Lanka. For them,
rninflata)yields licensing would set a stan-
i i us dard ofaccountability by
Cotera which they could be
judged, and which would
help the public distinguish
careful practice from quack-
ery. In a 26 May 1996 arti-
cle, the Associated Press
(AP) reported that, with a
new law, Vermont became
the eleventh state to license
naturopaths. Naturopathy is
a broad category that
includes practitioners of
herbal remedies along with
those of other nonsurgical,
nondrug treatments like
idAfrica manipulation. TheVermont
thw it law requires candidates for
hi6oi ucr licensing to complete four
es.Neens tea years ofpostgraduate uni-
paste in one versity study, as required in
d in081l40 0conventional Western med- "~i_i . **4. ^7%ofw cases ical training.Also, as in con-
hno 0 aciverse ventional medical training,
yalsohave the first two years must
.perinia. focus on standard human
biology. Recognition by
medical insurance, however,
remains rare. According to the AP, some
smaller insurance companies cover naturo-
pathictreatment, butmostdo not.
With the enactment of the DSHEA, a
series of seminars has brought together a
variety of concerned U.S. professionals for
the first time. In March 1995, FDA officials
met with more than 100 herbal medicine
providers, manufacturers, growers, and
researchers to examine the role ofbotanical
products in health care worldwide. A fol-
lowup seminar held in April 1996 focused
on scientific issues related to multicompo-
nent botanical products. Both seminars were
sponsored by the nonprofit Drug
Information Association with OAM and
FDAsupport.
The most recent workshop addressed
questions of botanical quality, purity, and
characterization. These technical issues pro-
vide a common language for chemists and
botanists from different constituencies to dis-
cuss herbal medicine. The 151 participants
at the April seminar came from universities,
botanical manufacturers, the FDA, and the
over-the-counter and prescription drug
industries.
Another seminar, planned for early
1997, will pursue issues of appropriate
dosage and efficacy, which methodologies
should be used to evaluate the effectiveness
of botanical products, and how researchers
can decide whether to study a botanical
product as a compound or search for single
activeingredients.
With this forum forboth regulators and
medicine manufacturers, a new framework
may be emerging. According to Floyd
Leaders, a pharmacologist and former OAM
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liaison with the FDA, the
dialogue generated by the
first botanical-related
OAM grants has led to tWO
significant changes in the
FDA policy governing
botanicals being considered
as drugs. First, there
appears to be a growing
willingness to reconsider
the "contribution to effica-
cy" requirements, which
obligate manufacturers to
demonstrate the contribu-
tion ofeach chemical com- °*
ponent of a single botani- Us** Treat
cal. For example, says ameobicd
Leaders, "Now the FDA cardiac
seems willing to look at Garptn
ginseng as ginseng.n
The second policy cholesterol, pr
shift relates to the animal mayhelp toco.
toxicology testing routinely protectag
required for a new product
before clinical trials can
begin. For botanical products already widely
used by humans, the need for these tests
could be relaxed, as they have been for sever-
al OAM grant studies on herbal products.
Freddie Ann Hoffman, deputy director
ofthe medicine staffin the FDA's Office of
Health Affairs, who chairs a new internal
FDA working group on botanical products,
agrees that these seminars have "opened a
novel opportunity for the FDA, the NIH
(OAM), industry, and academia to . . .
develop the scientific support required to
expand the range of products available" in
the United States. In an article coauthored
with Leaders in the January/February 1996
issue ofPharmaceuticalNews, Hoffman con-
cluded that recent policy changes differ "sig-
nificantly from previous [drug approval] pol-
icy" and provide a basis for broader policy
reviewwithin the FDA.
AResource under Pressure
With a growing global market, the sources of
herbal medicines are coming under intense
pressure. For example, Indonesia has seen an
explosive increase in demand, and a distress-
ing effect on wild plant populations in
forests. In the last 20 years, the expanding
herbal medicine industries have pried open a
huge market using quality packaging and
advertising, notes Satyawati Hadi, a scientist
at the Forest Products Research and
Development Center in Bogor, Indonesia.
The industries' consumption of symplicia
(dried natural medicinal materials) has
grown from 59 tons in 1972 to 7,784 tons
in 1992. "Continuous harvesting without
establishing plantations may result in the
tingr -tsei
ic;h yam
n.t kp;)
gtm
extinction ofsome ofthe species," Hadi cau-
tions. Hadi and others urge
-M,'2 more regulated harvests,
increased cultivation, and
an equitable sharing of
profits, which encourages
conservation bycollectors.
The supplyproblem is
by no means limited to
developing countries. In
the United States it is com-
pounded by a lack of
research on plant proper-
ties. "Most American med-
icinal plants have yet to be
hifla thoroughly investigated in
;infctions, terms ofpharmacology and
ate, and chemistry," Steven Foster bemis. and James Duke note in A
aberiahoand Field Guide to Medicinal
also reduces Plants: Eastern and Central
Ltsblooddots, North America. "Visiting
Aldiabetesand European and Chinese
st cancer. medical botanists ... cau-
tion that we should con-
serve [ourwildherbs]."
American ginseng harvests are regulated
by law, but that has not prevented a danger-
ous rise in harvests ofwild ginseng plants
from forests as prices have soared. For states
likeVirginia andWestVirginia, theevidence
suggests that harvests have already out-
stripped the natural productivity of these
populations. Species ofechinacea are similar-
lythreatened.
Some suggest that such alarms are over-
stated, that in fact the market demand for a
particular species fuels the search for resolu-
tion of any shortage. The February 1996
issue of Fortune examined the sequence of
events in which taxol from the Pacific yew
(Taxus brevifolia) was found to be effective
against ovarian cancer, then endangered by
the harvests needed for research anddevelop-
ment. It was finally rescued by research that
discovered a semisynthetic version, involving
a hybrid yew that could be grown on planta-
tions. "[T]he next time the newspapers are
full ofaseeminglyinsoluble problem," noted
the artide, "consider what the market might
do tohelp solve it."
Nevertheless, between the perception
of a supply shortage and its resolution, a
popular species could become extinct; it can
take seven years to grow a harvestable gin-
seng root. In the case of taxol, a self-
imposed harvest limit probably helped pre-
vent this. An artide in the April 1996 issue
of Environmental Health Perspectives noted
the public health consequences ofbiodiver-
sity loss in a case where the NCI harvested
the entire known adult population of a
shrub containing the anticancer compound
maytansine.
An "early warning" system based on
projections ofgrowing demand and existing
production capability (both natural and cul-
tivated) could signal which species require
urgent action. "Putting together a list ofpri-
ority species and those subject to depletion
would not be too difficult," says Robert
McCaleb, director of the Herb Research
Foundation in Boulder, Colorado. While
biodiversity loss and its consequences for
botanical medicines has yet to enter the pub-
lic debate over these products, it could be a
rallying point for resource conservation as
well as forpublichealthplanning.
Educating the public is crucial.
"Consumers need to be aware that there are
environmentally sound ways and irresponsi-
ble ways to collect these products," says
McCaleb. With this awareness, the public
can influence harvesting methods. For exam-
ple, almost all cultivated echinacea is E. pur-
purea, says McCaleb, while almost all E.
angustifolia is harvested from the wild. By
buying only E. purpurea products, con-
sumers can encourage cultivation.
This example underscores the widely
agreed-upon need for better consumer infor-
mation, including more detailed product
labels. Other countries' experiences and new
technologies for chemical characterization
appear to be leading the United States
toward the scrutiny and integration of
knowledge on herbal medicines that it has
resisted.
"We need good science to support these
products," says Leaders. "Now we're at the
stage to consider, 'What is good science? Is
this the best way to test these products?"'
Withgrowingmarketdemand for reasonably
priced and time-tested medicines, and with
the legislative prodding ofthe DSHEA, the
U.S. medical and regulatory systems are
being forced to address thisveryquestion. In
the meantime, more precise labels and a bet-
ter informed public would mark a step
towardsafelysharingIbuNining's secret.
DavidTaylor
Graphic text source: Alternative Medicine:
Expanding Medical Horizons. A Report to the
NationalInstitutesofHeafth onAltemativeMedical
Systems and Practices in the United States, pre-
pared under the auspices of the Workshop on
Alternative Medicine, Chantilly , Virginia, Sep-
tember14-16(1992).
Photo credits: Photos of milk thistle, purple cone-
flower, ginkgo, and lobelia were obtained from the
Southwest School of Botanical Medicine in
Albuquerque, New Mexico home page (directed
by Michael Moore) located at http://chili.rt66.-
com/hrbmoore/HOMEPAGE/HomePage.html.
Individual photographers are credited where
available.
Volume 104, Number9, September 1996* Environmental Health Perspectives 928